Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may unlock hidden cause of heart failure

NCT ID NCT02347722

Diagnosis Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether existing blood markers can accurately identify the underlying cause of heart failure in 511 patients. Researchers aim to improve diagnosis and potentially reduce healthcare costs by avoiding unnecessary tests. Participants were recently diagnosed with heart failure and had their blood analyzed for specific biomarkers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple blood test that helps doctors quickly identify the root cause of heart failure, enabling more targeted treatment.
What could go wrong
This is an observational study, not a treatment trial. The biomarkers may not prove accurate enough in practice, and results may not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

511 people

The number who actually took part.

Start date

May 2015

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The retrospective cohort consists of stored blood samples from various biobanks. The prospective cohort consists of patients admitted to academic hospitals or outpatient clinics with symptomatic heart failure diagnosed within 2 years. The volunteer cohort consists of age matched healthy volunteers

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients admitted with symptomatic heart failure, diagnosed within 2 years. * Diagnosis of congestive heart failure using the modified Framingham criteria: Simultaneous presence of at least 2 major criteria or 1 major criterion in conjunction with 2 minor criteria or a previous clear diagnosis of heart failure. Major criteria: * Paroxysmal nocturnal dyspnea or orthopnea * Neck vein distention * Rales/Crackles (\>10 cm from base of lungs) * Acute pulmonary edema * S3 gallop * Increased central venous pressure (\>16 cm H2O at right atrium) * Hepatojugular reflux * Weight loss \>4.5 kg in 5 days in response to treatment Echocardiographic left ventricular dysfunction Minor criteria: * Bilateral ankle edema * Nocturnal cough * Dyspnea on exertion * Hepatomegaly * Pleural effusion * Weight loss \>4.5 kg caused by heart failure where factors other than treatment of CHF could have contributed to the weight loss * Tachycardia (heart rate \>120 beats/min) Minor criteria are acceptable only if they cannot be attributed to another medical condition (such as pulmonary hypertension, chronic lung disease, cirrhosis, ascites, or the nephrotic syndrome). Exclusion Criteria: * Patients unable to provide blood sample * Patients unable to provide consent * Patient with life expectancy of less than 6 months, or has major co-morbidities. * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial. * Participants who have participated in another research trial involving an investigational product in the past 30 days.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure

Contacts and locations

Locations

  • University of Ottawa Heart Institute

    Ottawa, Ontario, K1Y 4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.